6.51
-0.50 (-7.07%)
| Penutupan Terdahulu | 7.00 |
| Buka | 6.49 |
| Jumlah Dagangan | 2,536,946 |
| Purata Dagangan (3B) | 4,285,933 |
| Modal Pasaran | 1,046,290,240 |
| Harga / Jualan (P/S) | 1.56 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 8 May 2025 - 12 May 2025 |
| Margin Keuntungan | -27.49% |
| Margin Operasi (TTM) | -142.09% |
| EPS Cair (TTM) | -1.23 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -69.70% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 179.90% |
| Nisbah Semasa (MRQ) | 0.980 |
| Aliran Tunai Operasi (OCF TTM) | -87.26 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -175.64 M |
| Pulangan Atas Aset (ROA TTM) | -8.63% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Novavax, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.5 |
| Purata | -1.50 |
|
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 8.80% |
| % Dimiliki oleh Institusi | 60.18% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Shah Capital Management | 31 Dec 2024 | 11,148,846 |
| Tsp Capital Management Group, Llc | 31 Dec 2024 | 1,358,565 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 31 Mar 2025 | CNBC | Vaccine stocks fall after key FDA official resigns in protest of RFK Jr. |
| 11 Mar 2025 | Pengumuman | Novavax Announces Changes to Board of Directors |
| 27 Feb 2025 | Pengumuman | Novavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights |
| 27 Feb 2025 | Pengumuman | Novavax to Participate in Upcoming March Investor Conferences |
| 20 Feb 2025 | Pengumuman | Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025 |
| 04 Feb 2025 | CNBC | Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary |
| 23 Jan 2025 | Pengumuman | Brian Rosen, Commercial Strategy Senior Executive, Appointed as Director of Capstone Companies, Inc. |
| 13 Jan 2025 | CNBC | Moderna stock plunges nearly 17% after company lowers 2025 sales forecast by $1 billion |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |